Please assess the completion status of the following clinical trial:

Trial Title: Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Primary Fibromyalgia (2010 ACR criteria)~* Male or female 18-75 years old~* Patients currently receiving pharmacologic treatment for depression should have been clinically stable for at least 3 months prior to randomization, and on stable doses of antidepressants during this 3 month time frame.~* Willing and able to withdraw specific therapies (ask PI)~* If female, medically acceptable form of contraception or not of child bearing potential.~* Provide written informed consent to participate.~* Willing and able to comply with all protocol specified requirement.~Exclusion Criteria:~* Arthritis, lupus and other systemic auto-immune diseases~* Regional or persistent pain that could interfere with assessment of fibromyalgia pain~* Bipolar and psychotic disorders~* Increased risk of suicide~* Significant clinical (cardiac, systemic infection, systemic corticosteroid requirement, drug/alcohol abuse) or laboratory abnormalities.~* Inability to wash-out specific medications (ask PI)~* Known hypersensitivity to cyclobenzaprine~* Others: seizure disorders, severe/untreated sleep apnea, BMI\>45

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TNX-102 SL Tablet, 2.8 mg (Type: EXPERIMENTAL): 1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
- Placebo SL Tablet (Type: PLACEBO_COMPARATOR): 1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).